Table 2.

SCr levels in the LTE and Phase 3 studies: stabilization of SCr levels in the LTE studies

SCr increase at EoT in Phase 3 (%)	Mean (%) increase from baseline at EoT in index study, mg/dl	Mean (%) increase from baseline at last observed visit in LTE, mg/dl
≤10% (n = 909)	0.00 (0.3)	0.05 (7.5)
>10 to <33% (n = 653)	0.13 (18.6)	0.13 (18.5)
≥33 to ≤50% (n = 82)	0.25 (38.2)	0.24 (36.5)
>50% (n = 7)	0.32 (56.0)	0.26 (44.9)

EoT, end of treatment; LTE, long-term extension; SCr, serum creatinine.